Full Text
The Full Text of this article is available as a PDF (54.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brooks P. M. Clinical management of rheumatoid arthritis. Lancet. 1993 Jan 30;341(8840):286–290. doi: 10.1016/0140-6736(93)92628-7. [DOI] [PubMed] [Google Scholar]
- Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
- Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
- Jespers L. S., Roberts A., Mahler S. M., Winter G., Hoogenboom H. R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 1994 Sep;12(9):899–903. doi: 10.1038/nbt0994-899. [DOI] [PubMed] [Google Scholar]
- Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
- Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maini R. N., Brennan F. M., Williams R., Chu C. Q., Cope A. P., Gibbons D., Elliott M., Feldmann M. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol. 1993 Mar-Apr;11 (Suppl 8):S173–S175. [PubMed] [Google Scholar]
- Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
- Rankin E. C., Choy E. H., Kassimos D., Kingsley G. H., Sopwith A. M., Isenberg D. A., Panayi G. S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995 Apr;34(4):334–342. doi: 10.1093/rheumatology/34.4.334. [DOI] [PubMed] [Google Scholar]
- Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995 Apr;7(3):251–259. doi: 10.1006/cyto.1995.0029. [DOI] [PubMed] [Google Scholar]
- van Gestel A. M., Prevoo M. L., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B., van Riel P. L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996 Jan;39(1):34–40. doi: 10.1002/art.1780390105. [DOI] [PubMed] [Google Scholar]